Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chart: "JMFF's Winners"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Among the recipients of Michael J. Fox Foundation grants, ShanRx, in Woodside, Calif., is identifying neuroprotective drugs that work in the P13K signaling pathway. With the MJFF funding, the start-up aims to identify candidates and establish safety and efficacy in a rat model. Recently public Omeros, in Seattle, will get up to $465,000 from the foundation to further investigate a novel target (cyclic nucleotide phosphodiesterase type 7, implicated in movement disorders) it identified under an earlier MJFF deal. Another winner, California drug discovery and diagnostics play KineMed, is working on a way of showing that cerebrospinal fluid-based biomarkers can be used to track the progress of Parkinson's disease and possibly to discover new points of therapeutic intervention by shedding light on the pathogenesis of the disease.

You may also be interested in...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals


Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care

The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts